A review of FDA-approved acute myeloid leukemia therapies beyond ‘7 + 3’-Reference-Cited by-同舟云学术

A review of FDA-approved acute myeloid leukemia therapies beyond ‘7 + 3’

Published:2021-01-19 Issue:2 Volume:14 Page:185-197
ISSN:1747-4086
Container-title:Expert Review of Hematology
language:en
Short-container-title:Expert Review of Hematology

Author:

Bazinet Alexandre¹,Assouline Sarit¹

Affiliation:

1. Department of Hematology, Jewish General Hospital, McGill University, Montreal, QC, Canada

Publisher

Informa UK Limited

Subject

Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/17474086.2021.1875814

Reference136 articles.

1. Acute Myeloid Leukemia

2. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

3. SEER cancer statistics review 1975–2016. 2019 [cited 2020 Sep 23]. Available from: https://seer.cancer.gov/csr/1975_2016/

4. National Cancer Institute: drugs approved for leukemia. 2020 [cited 2020 Nov 30]. Available from: https://www.cancer.gov/about-cancer/treatment/drugs/leukemia#

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. p110CUX1 promotes acute myeloid leukemia progression via regulating pyridoxal phosphatase expression and activating PI3K/AKT/mTOR signaling pathway;Molecular Carcinogenesis;2024-07-12

2. Autophagy and inflammasome molecular interplay and activation predict poor response to FLT3 inhibitors in patients with FLT3-ITD acute myeloid leukemia;2024-06-18

3. FLT3-selective PROTAC: Enhanced safety and increased synergy with Venetoclax in FLT3-ITD mutated acute myeloid leukemia;Cancer Letters;2024-06

4. Piplartine eliminates CD34 + AML stem/progenitor cells by inducing oxidative stress and suppressing NF-κB signalling;Cell Death Discovery;2024-03-19

5. Inhibition of NRF2 enhances the acute myeloid leukemia cell death induced by venetoclax via the ferroptosis pathway;Cell Death Discovery;2024-01-18